Eculizumab

依库珠单抗

Report date: 2026/03/31 20:00:21
First In Class

Base Information

Drug NameEculizumab
Drug Alias Name依库珠单抗Monoclonal antibody 5G1-1依库丽单抗Anti-C5 monoclonal antibody 5G1-1Soliris +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionComplement C5 inhibitors
TargetsComplement C5
Therapy Area/IndicationsRejection of organ transplantationRejection of renal transplantationParturition +[25] 
Global Approved IndicationsHemoglobinuria, ParoxysmalAtypical Hemolytic Uremic Syndrome
Approved Indications in ChinaHemoglobinuria, ParoxysmalAtypical Hemolytic Uremic Syndrome
Original Approved Country/TerritoryUnited States
Original Approved Date2007/03/16
Country/TerritoryCzechiaBelgiumCanada +[34] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAlexion Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of NancyAlexion Europe SasJohns Hopkins University +[5] 
Inactive CompaniesThe Brigham and Women's HospitalGenerium PharmaceuticalsYale University +[14] 
Active IndicationsInfant, Newborn, DiseasesHemoglobinuria, ParoxysmalPre-Eclampsia +[9] 
Inactive IndicationsRejection of organ transplantationRejection of renal transplantationParturition +[16] 

Other Information

ATC CodeL04AJ01
Related LinksWikipediaDrugBankKEGG